INTERNATIONAL FORUM ON HPV AND HEAD & NECK CANCER
Monday, Jan. 18, 2021 • Tuesday, Jan. 19, 2021
Coordination: E. RETTIG (USA), P. KLUSSMANN (Germany)
The EUROGIN HPV and Head & Neck Cancer Forum highlights areas of active investigation in the field of HPV and head and neck cancers. This year's forum will offer an extended review of screening for early cancer detection that will occupy two sessions, molecular characterization and potential biomarkers for prognosis and monitoring of HPV related oropharyngeal cancer patients, new insights on emerging treatment strategies and the role of HPV in benign disease such as recurrent respiratory papillomatosis
A dedicated debate session will focus on the controversies regarding the impact of HPV infection on oro-pharyngeal cancer, including diagnosis, management and decision making.
Overview of Sessions
Subject to change
Speakers* are to be confirmed
Monday, January 18, 2021
Management
Chair: A. Psyrri (Greece)
HN 01
8:00 - 9:30
- Diagnosis: Work-up of unknown primary • Holsinger* (US)
- Updates in intensification • Chia Jung Busch (Europe)
- Surgical deintensification of HPV-OPC • Moore* (US)
- Role of biomarkers in HPV-OPC treatment • Chera* (US)
- High-risk & recurrent disease • Mehanna (Europe)
- Discussion
Epidemiology & prevention
Chair: P. Bossi (Italy)
HN 02
9:30 - 11:00
- HPV in non-oropharynx SCCa • TBD
- HPV vaccination and HPV-OPC prevention • Brogli Dappen (Europe)
- Updates in epidemiologic trends - oral HPV infection & HPV-OPC • Dahlstrom* (US)
- Biomarkers for HPV-OPC • Prigge (Europe)
- Familial occurrence of OPSCC and other HPV-associated cancers • Hemminki (Europe)
- Discussion
Screening
Chair: T. Waterboer (Germany)
HN 03
14:00 - 15:30
- Screening for HPV-OPC: Are we there yet? • Robbins (Europe)
- Risk-stratified screening of OPSCC - proof of concept trial • M. Lehtinen (Europe)
- HIV Endeavor (HPV16 AB Detection as an Early Marker of OPSCC among men living with HIV) • Lang Kuhs* (US)
- Cost-effectiveness of OPSCC elimination • Vänskä (Europe)
- Screening trial updates • Sturgis* (US)
- Discussion
Survivorship & Surveillance
Chair: P. Klussmann (Germany)
HN 04
16:00 - 17:30
- HPV-OPC surveillance: standard of care & emerging biomarkers • Rettig* (US)
- Patient concerns, priorities & decision-making • Windon* (US)
- Swallowing evaluation, interventions and outcomes • Starmer* (US)
- Impact of deintensification on HRQOL outcomes • Simon (Europe)
- The psychology of surviving a sex / STI-linked cancer like HPV-associated cancer • Nosayaba Osazuwa-Peters* (US)
- Discussion
Submitted Abstracts
Chair: Speel (Europe)
HN 05
17:30 - 19:00
Tuesday, January 19, 2021
Carcinogenesis & molecular characterization
Chair: Klozar (Czech Republic)
HN 06
8:00 - 9:30
- Impact of smoking vs. HPV on carcinogenesis • Zevallos* (US)
- Single cell sequencing • Puram* (US)
- HPV viral integration • Virani* (Europe)
- Molecular modifiers of prognosis in HPV-OPC • Licitra (Europe)
- Liquid biopsy for HPV-OPC • Wuerdeman (Europe)
- Discussion
Immunologic considerations
Chair: Sikora* (USA)
HN 07
10:00 - 11:30
- Immunologic landscape in HPV+ vs HPV- HNSCC • Sikora* (US)
- Immune microenvironment in HPV-OPC • Dalianis (Europe)
- HPV-specific T cell response • Van der Burg (Europe)
- Role of immunotherapy in HPV-OPC • Hanna* (US)
- Enhancing immune response to HPV-OPC: tumor vaccines, CAR-T therapy • TBD
- Discussion
RRP
Chair: S. Best* (USA)
HN 08
14:15 - 15:45
- Immune therapy for RRP • TBD
- Vaccination and RRP • Dikers (Europe)
- TBD • Allen* (US)
- TBD • S. Best* (US)
- Discussion
Submitted Abstracts
Chair: TBD
HN 09
16:15 - 19:15
EUROGIN (EUropean Research Organisation on Genital Infection and Neoplasia) brings together clinicians and scientists whose work is related to genital infections and neoplasia.
